研报掘金丨东方证券：予大参林“买入”评级，目标价20.16元

Group 1 - The core viewpoint of the article highlights that DSR Pharmacy has shown impressive net profit performance and significant results in cost reduction and efficiency improvement [1] - The report indicates that compliance costs for physical pharmacies are continuously increasing due to factors such as regular inspections, special checks, and mandatory application of traceability codes [1] - The industry is experiencing a faster pace of clearing out weaker players as a result of the increasing compliance costs [1]